Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
January 21, 2021 01:00 ET
|
Addex Therapeutics
First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 Geneva, Switzerland, January 21, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical...
Addex to Present at the Baader Helvea Swiss Equities Conference
January 12, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 12, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities
January 11, 2021 16:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Announces Pricing of $10.0 Million Global Offering
January 06, 2021 21:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities
December 14, 2020 12:22 ET
|
Addex Therapeutics
Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Reports Q3 2020 Financial Results and Provides Corporate Update
November 03, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 3, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
ADDEX THERAPEUTICS TO RELEASE Q3 2020 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 3rd, 2020
November 02, 2020 01:06 ET
|
Addex Therapeutics
Geneva, Switzerland, November 2, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its Q3 2020...
Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration
November 02, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 2, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that the...
Addex to Present at the Investora Conference
September 23, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 23, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that...
Addex Therapeutics to Participate at the H.C. Wainwright 22nd Annual Global Investment Conference
September 14, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 14, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that...